Stryker this week said it launched its Surpass Evolve flow diverter after it received FDA approval.
The flow diverter is a 64-wire cobalt-chromium device designed to re-direct blood flow and promote aneurysm healing. It follows the company’s launch of Surpass Streamline in 2018.
“This device builds on the success of Surpass Streamline, offering a highly optimized and easy to use flow diverter. By increasing the braid angle, the novel 64-wire device delivers excellent flow diversion and a highly flexible implant for enhanced vessel wall contact. The higher mesh density of Surpass Evolve versus traditional 48-wire flow diverters may lead to faster aneurysm occlusion for patients,” Dr. Ajay Wakhloo, the first physician to complete a commercial case in the U.S. with the device, said in a news release.
Stryker launched the Surpass Evolve in Europe last year and said it has since been approved in over 45 countries. More than 1,500 patients have been treated with the technology and physicians have reported the device being easier to use than its predecessor.
“Surpass Evolve is our fourth PMA approval and second flow diverter approved by the FDA in the last two years. It augments our robust hemorrhagic portfolio and reflects our ongoing commitment to invest in technologies that will drive improved patient outcomes. Stryker is dedicated to working with our customers to bring life-saving technologies to patients suffering from brain aneurysms,” said Mark Paul, president of Stryker’s neuromuscular division.